A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy
Primary Investigator
Franson, Andrea
Status
OPEN TO ACCRUAL
Phase
II
NCT Number
NCT06413706
UM Number
2024.079
Age Group
Children
Management Group
CTSU - Michigan
Oncology Group
Childhood Cancers
ID (Protocol)
53736
Secondary Protocol No
HUM00253825
Scope
Unspecified
Sponsor Type
Industry
Disease Site
Brain and Nervous System
Summary
The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy.
Your participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond.
Your participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond.
Eligibility:
For more information about a trial or help finding one, contact the Cancer AnswerLine at 800-865-1125 or [email protected]